Modelos animales de carcinoma hepatocelular y sus aplicaciones en biomedicina

Irati López de la Pisa

doi:10.18002/ambioc.v0i18.6564

Autores

Irati López de la Pisa

DOI:

https://doi.org/10.18002/ambioc.v0i18.6564

Palavras-chave:

Antioxidantes, carcinoma hepatocelular, inhibidores de quinasas, metabolómica, modelos animales, terapeútica

Resumo

El carcinoma hepatocelular (CHC) es la segunda causa de muerte por cáncer en todo el mundo y el subtipo histológico más común cáncer primario de hígado. Teniendo este escenario en consideración, los modelos animales de CHC son esenciales para entender la enfermedad a nivel molecular, para el desarrollo de nuevas vías de tratamiento y para la realización de ensayos preclínicos. La presente revisión se centra en las características de los modelos animales químicamente inducidos, de implantación y de los modelos animales de enfermedad de hígado graso no alcohólico/esteatohepatitis no alcohólica (NAFLD/NASH). Además, dado que los métodos de detección identifican el CHC en etapas tardías, su naturaleza asintomática en etapas tempranas y su refractariedad a casi todas las terapias actuales, las nuevas líneas de investigación junto con las nuevas y actuales vías de tratamiento también se discuten en esta revisión.

Downloads

Não há dados estatísticos.

Referências

Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A.,

Kumar, D. P., Daita, K., Min, H. K., Mirshahi, F., et al. 2016. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cáncer. Journal of Hepatology, 65:579-588

Baba, H., Tsuneyama, K., Nishida, T., Hatta, H., Nakajima, T., Nomoto, K., Hayashi, S.,

Miwa, S., Nakanishi, Y., Hokao, R. e Imura, J. 2014. Neonatal streptozotocin treatment causes type 1 diabetes and subsequent hepatocellular carcinoma in DIAR mice fed a normal diet. Hepatology International, 8:415-424

Beyoğlu, D. e Idle, J. R. 2020. Metabolomic and lipidomic biomarkers for premalignant

liver disease diagnosis and therapy. Metabolites, 10:50

Caviglia J.M. y Schwabe R.F. 2015. Mouse Models of Liver Cancer, en Eferl R. y Casanova E. (eds.) Mouse Models of Cancer. New York: Humana Press, pp. 165-183.

De Minicis, S., Kisseleva, T., Francis, H., Baroni, G. S., Benedetti, A., Brenner, D., Alvaro,

D., Alpini, G. y Marzioni, M. 2013. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Digestive and Liver Disease, 45:450-459

Fang, D., Xiong, Z., Xu, J., Yin, J. y Luo, R. 2019. Chemopreventive mechanisms of

galangin against hepatocellular carcinoma: a review. Biomedicine and Pharmacotherapy, 109:2054-2061

Fernández-Palanca, P., Fondevila, F., Méndez-Blanco, C., Tuñón, M. J., González-Gallego, J. y Mauriz, J. L. 2019. Antitumor effects of quercetin in hepatocarcinoma in vitro and in vivo models: a systematic review. Nutrients, 11:2875

Fernández-Varo, G., Perramón, M., Carvajal, S., Oró, D., Casals, E., Boix, L., Oller, L.,

Macías-Muñoz, L., Marfá, S., Casals, et al. 2020. Bespoken nanoceria: a new effective treatment in experimental hepatocellular carcinoma. Hepatology, 72:1267-1282

García, E. R., Gutierrez, E. A., Melo, F. C. S. A. D., Novaes, R. D. y Gonçalves, R.V. 2018.

Flavonoids effects on hepatocellular carcinoma in murine models: a systematic review. Evidence-Based Complementary and Alternative Medicine, 28:6328970

Gong, Z. G., Zhao, W., Zhang, J., Wu, X., Hu, J., Yin, G. C. y Xu, Y. J. 2017. Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus- related cirrhosis. Oncotarget, 8:63890-63900

Guo, W., Tan, H. Y., Wang, N., Wang, X. y Feng, Y. 2018. Deciphering hepatocellular

carcinoma through metabolomics: from biomarker discovery to therapy evaluation. Cancer Management and Research, 10:715-734

He, L., Tian, D. A., Li, P. Y. y He, X. X. 2015. Mouse models of liver cancer: progress and

recommendations. Oncotarget, 6:23306-23322

Heindryckx, F., Colle, I. y Van Vlierberghe, H. 2009. Experimental mouse models for

hepatocellular carcinoma research. International Journal of Experimental Pathology, 90:367-386

Henderson, J. M., Zhang, H. E., Polak, N. y Gorrell, M. D. 2017. Hepatocellular carcinoma: mouse models and the potential roles of proteases. Cancer Letters, 387:106-113

Hu, T., Sun, D., Zhang, J., Xue, R., Janssen, H. L., Tang, W. y Dong, L. 2018. Spermine

oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma.

Hepatology Research, 48:967-977

Jacobs, A., Warda, A. S., Verbeek, J., Cassiman, D. y Spincemaille, P. 2016. An overview

of mouse models of nonalcoholic steatohepatitis: from past to present. Current Protocols in Mouse Biology, 6:185- 200

INNOVACIÓN DOCENTE

Jung, J. 2014. Human tumor xenograft models for preclinical assessment of anticancer

drug development. Toxicological Research, 30:1-5

Lau, J. K. C., Zhang, X. y Yu, J. 2017. Animal models of non-alcoholic fatty liver disease:

current perspectives and recent advances. The Journal of Pathology, 241:36-44

de Lima, V. M., Oliveira, C. P., Alves, V. A., Chammas, M. C., Oliveira, E. P., Stefano, J. T., de Mello, E. S., Cerri, G. G., Carrilho, F. J. y Caldwell, S. H. 2008. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. Journal of Hepatology, 49:1055-1061

Mazzanti, R., Gramantieri, L. y Bolondi, L. 2008. Hepatocellular carcinoma: epidemiology and clinical aspects. Molecular Aspects of Medicine, 29:130-143

McGlynn, K. A., Hunter, K., LeVoyer, T., Roush, J., Wise, P., Michielli, R. A., Shen, F. M.,

Evans, A. A., London, W. T. y Buetow, K. H. 2003. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Research, 63:4594-4601

Newell, P., Villanueva, A., Friedman, S. L., Koike, K. y Llovet, J. M. 2008. Experimental

models of hepatocellular carcinoma. Journal of Hepatology, 48:858-879

Rao, Q., You, A., Guo, Z., Zuo, B., Gao, X., Zhang, T., Du, Z., Wu, C. y Yin, H. F. 2016.

Intrahepatic tissue implantation represents a favorable approach for establishing orthotopic transplantation hepatocellular carcinoma mouse models. PLoS ONE, 11:1-12

Santos, N. P., Colaço, A. A. y Oliveira, P. A. 2017. Animal models as a tool in hepatocellular carcinoma research: a review. Tumor Biology, 39: 1-20

Sasaki, R., Kanda, T., Fujisawa, M., Matsumoto, N., Masuzaki, R., Ogawa, M., Matsuoka,

S., Kuroda, K. y Moriyama, M. 2020. Different mechanisms of action of regorafenib and lenvatinib on toll-like receptor- signaling pathways in human hepatoma cell lines. International Journal of Molecular Sciences, 21:3349

Shankaraiah, R. C., Gramantieri, L., Fornari, F., Sabbioni, S., Callegari, E. y Negrini, M.

Animal models of hepatocellular carcinoma prevention. Cancers, 11:1-15

Stefaniuk, P., Cianciara, J. y Wiercinska-Drapalo, A. 2010. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology, 16:418-424

Takahashi, T., Nishida, T., Baba, H., Hatta, H., Imura, J., Sutoh, M., Toyohara, S., Hokao, R., Watanabe, S., Ogawa, et al. 2016. Histopathological characteristics of glutamine synthetase-positive hepatic tumor lesions in a mouse model of spontaneous metabolic syndrome (TSOD mouse). Molecular and Clinical Oncology, 5:267-270

Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H. I., Hoshida, Y. y Friedman, S. L. 2018. A simple diet-and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. Journal of Hepatology, 69:385-395

Tsuneyama, K., Nishitsuji, K., Matsumoto, M., Kobayashi, T., Morimoto, Y., Tsunematsu, T. y Ogawa, H. 2017. Animal models for analyzing metabolic syndrome-associated liver diseases. Pathology International, 67:539-546

Wu, J. 2016. Utilization of animal models to investigate nonalcoholic steatohepatitisassociated hepatocellular carcinoma. Oncotarget, 7:42762-42776

Zhang, H. E., Henderson, J. M. y Gorrell, M. D. 2019. Animal models for hepatocellular

carcinoma. Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease, 1865:993-1002

Zhong, F., Zhou, X., Xu, J. y Gao, L. 2020. Rodent models of nonalcoholic fatty liver

disease. Digestion, 101:522-535